Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares IssuedShares OutstandingShares Outstanding
Ratios

Silence Therapeutics (SLN) Receivables Refunds (2018 - 2025)

Silence Therapeutics' Receivables Refunds history spans 8 years, with the latest figure at $2.6 million for Q4 2025.

  • On a quarterly basis, Receivables Refunds rose 69.29% to $2.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.6 million, a 69.29% increase, with the full-year FY2025 number at $2.6 million, up 69.29% from a year prior.
  • Receivables Refunds hit $2.6 million in Q4 2025 for Silence Therapeutics, up from $1.5 million in the prior quarter.
  • Over the last five years, Receivables Refunds for SLN hit a ceiling of $2.0 billion in Q1 2021 and a floor of $1.5 million in Q4 2024.
  • Historically, Receivables Refunds has averaged $123.9 million across 5 years, with a median of $5.1 million in 2023.
  • The widest YoY moves for Receivables Refunds: up 100.28% in 2021, down 99.88% in 2021.
  • Tracing SLN's Receivables Refunds over 5 years: stood at $9.4 million in 2021, then surged by 86.45% to $17.5 million in 2022, then grew by 25.33% to $21.9 million in 2023, then crashed by 92.96% to $1.5 million in 2024, then soared by 69.29% to $2.6 million in 2025.
  • Business Quant data shows Receivables Refunds for SLN at $2.6 million in Q4 2025, $1.5 million in Q4 2024, and $8.5 million in Q3 2024.